XML 49 R34.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue from Contracts with Customers (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Product sales, net |
Schedule of Disaggregation of Revenues | During the years ended December 31, 2024, 2023 and 2022, the Company recorded product sales, net, as follows:
|  | Year Ended December 31, |
(In thousands) |  | 2024 |  |  | 2023 |  |  | 2022 |
VIVITROL |  | $ | 457,315 |  |  | $ | 400,419 |  |  | $ | 379,478 |
ARISTADA and ARISTADA INITIO |  |  | 346,187 |  |  |  | 327,690 |  |  |  | 302,052 |
LYBALVI |  |  | 280,032 |  |  |  | 191,889 |  |  |  | 96,022 |
Total product sales, net |  | $ | 1,083,534 |  |  | $ | 919,998 |  |  | $ | 777,552 |
Manufacturing and royalty revenues |
Schedule of Disaggregation of Revenues | During the years ended December 31, 2024, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|  | Year Ended December 31, 2024 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 236,386 |  |  | $ | 236,386 |
VUMERITY |  |  | 39,292 |  |  |  | 94,755 |  |  |  | 134,047 |
RISPERDAL CONSTA |  |  | 23,172 |  |  |  | 272 |  |  |  | 23,444 |
Other |  |  | 56,962 |  |  |  | 23,256 |  |  |  | 80,218 |
|  | $ | 119,426 |  |  | $ | 354,669 |  |  | $ | 474,095 |
|  | Year Ended December 31, 2023 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 486,101 |  |  | $ | 486,101 |
VUMERITY |  |  | 42,886 |  |  |  | 86,440 |  |  |  | 129,326 |
RISPERDAL CONSTA |  |  | 36,123 |  |  |  | 1,153 |  |  |  | 37,276 |
Other |  |  | 63,489 |  |  |  | 27,196 |  |  |  | 90,685 |
|  | $ | 142,498 |  |  | $ | 600,890 |  |  | $ | 743,388 |
|  | Year Ended December 31, 2022 |
(In thousands) |  | Manufacturing Revenue |  |  | Royalty Revenue |  |  | Total |
Long-acting INVEGA products(1) |  | $ | — |  |  | $ | 115,655 |  |  | $ | 115,655 |
VUMERITY |  |  | 32,493 |  |  |  | 83,003 |  |  |  | 115,496 |
RISPERDAL CONSTA |  |  | 42,670 |  |  |  | 7,243 |  |  |  | 49,913 |
Other |  |  | 37,211 |  |  |  | 13,708 |  |  |  | 50,919 |
|  | $ | 112,374 |  |  | $ | 219,609 |  |  | $ | 331,983 |
(1) “long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |